Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002013061 | SCV002291057 | uncertain significance | Walker-Warburg congenital muscular dystrophy | 2021-09-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with FKTN-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces serine with arginine at codon 2 of the FKTN protein (p.Ser2Arg). The serine residue is moderately conserved and there is a moderate physicochemical difference between serine and arginine. |
Ambry Genetics | RCV004045971 | SCV005037356 | uncertain significance | Cardiovascular phenotype | 2024-03-13 | criteria provided, single submitter | clinical testing | The p.S2R variant (also known as c.6T>G), located in coding exon 1 of the FKTN gene, results from a T to G substitution at nucleotide position 6. The serine at codon 2 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |